|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.750 USD | -4.23% |
|
-20.03% | -75.94% |
| 07-06 | Curis Consents First Six Patients in Takeaim Cll Study | CI |
| 07-06 | Curis Consents 6 Patients in Phase 2 Trial of Emavusertib in Chronic Lymphocytic Leukemia | MT |
| Market Cap | 9.67M 8.48M 7.85M 7.23M 13.67M 925M 13.93M 93.59M 36.71M 454M 36.3M 35.51M 1.57B | P/E 2026 * |
-0.16x | P/E 2027 * | -0.24x |
|---|---|---|---|---|---|
| Enterprise Value | 9.67M 8.48M 7.85M 7.23M 13.67M 925M 13.93M 93.59M 36.71M 454M 36.3M 35.51M 1.57B | EV / Sales 2026 * |
5.52x | EV / Sales 2027 * | 0.76x |
| Free-Float |
91.97% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Curis, Inc.
| 1 day | -4.23% | ||
| 1 week | -20.03% | ||
| Current month | -54.51% | ||
| 1 month | -42.88% | ||
| 3 months | -61.69% | ||
| 6 months | -73.51% | ||
| Current year | -75.94% |
| 1 week | 4.46 |  | 5.9 |
| 1 month | 3.61 | | 11.4 |
| Current year | 3.61 | | 24.2 |
| 1 year | 3.61 | | 39 |
| 3 years | 3.61 | | 349.8 |
| 5 years | 3.61 | | 3,616 |
| 10 years | 3.61 | | 7,440 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Dentzer
CEO | Chief Executive Officer | 59 | 2018-09-23 |
Diantha Duvall
DFI | Director of Finance/CFO | 54 | 2022-08-04 |
Nick Pelletier
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Kenneth Kaitin
BRD | Director/Board Member | 73 | 2003-10-31 |
Martyn Greenacre
CHM | Chairman | 84 | 2017-05-15 |
Marc Rubin
BRD | Director/Board Member | 71 | 2010-06-02 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 07-06 | Free | Chairman | 6,800 | 0.0174% | ||
| 07-06 | Free | Executive/Senior Manager | 48,285 | 0.1239% | ||
| 07-06 | Free | Director | 6,800 | 0.0174% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.23% | -20.03% | -87.37% | -98.58% | 9.67M | |
| +0.44% | +2.51% | +4.36% | +10.27% | 50.73B | |
| -1.57% | -3.18% | +379.41% | +593.37% | 39.73B | |
| -0.14% | +0.77% | +29.61% | -5.50% | 34.69B | |
| +1.76% | -1.78% | +20.55% | +53.38% | 33.21B | |
| -0.06% | -4.63% | +2.94% | +31.65% | 26.76B | |
| -1.93% | -1.01% | - | - | 16.8B | |
| -1.49% | -6.18% | +65.50% | +120.53% | 15.37B | |
| +0.78% | +0.20% | +14.69% | +17.08% | 13.78B | |
| -0.97% | -2.83% | +11.09% | -33.29% | 12.85B | |
| Average | -0.77% | -3.73% | +48.98% | +76.55% | 24.39B | |
| Weighted average by Cap. | -0.24% | -0.38% | +81.17% | +124.09% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.75M 1.53M 1.42M 1.31M 2.47M 167M 2.52M 16.94M 6.65M 82.25M 6.57M 6.43M 284M | 12.75M 11.18M 10.36M 9.53M 18.03M 1.22B 18.38M 123M 48.42M 599M 47.88M 46.83M 2.07B |
| Net income | -45.15M -39.6M -36.68M -33.75M -63.83M -4.32B -65.08M -437M -171M -2.12B -170M -166M -7.33B | -35.44M -31.09M -28.79M -26.49M -50.11M -3.39B -51.08M -343M -135M -1.67B -133M -130M -5.75B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-13 | US$4.750 | -4.23% | 89,876 |
| 26-07-10 | US$4.960 | 0.00% | 61,526 |
| 26-07-09 | US$4.960 | +0.51% | 37,742 |
| 26-07-08 | US$4.935 | -6.71% | 102,354 |
| 26-07-07 | US$5.290 | -10.94% | 206,466 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CRIS Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
